OUR PRODUCTS
Our first generation of products demonstrate the potential of our technology platform to produce sustainable and affordable chemicals for a wide range of markets. A promising pipeline of products are currently in development.
DEVELOPMENT EFFICIENCY
Go from concept to commercial faster with our standardized, scalable, and proven technology platform that’s Made to Scale™.
![Asset 5](https://dmcbio.com/wp-content/uploads/2021/12/Asset-5.png)
DEVELOPMENT
EFFICIENCY
Go from concept to commercial faster with our standardized, scalable, and proven technology platform.
![Layer 2](https://dmcbio.com/wp-content/uploads/2021/12/Layer-2.png)
SUSTAINABLE
PRODUCTION
Our L-alanine production in Europe will reduce CO2 emissions by over 90%, compared to imported L-alanine. That’s equivalent to removing more than 60,000 cars from the road, annually.
![Layer 3](https://dmcbio.com/wp-content/uploads/2021/12/Layer-3.png)
SUPPLY CHAIN
SECURITY
Cost-competitive, local production using agricultural feedstocks enables our customers to diversify their supply chain, making them more resilient to the next global shift.
COLLABORATING WITH DMC
DMC’s innovative technology and metabolic engineering expertise enables a broad range of bio-based chemicals to be commercialized rapidly and produced cost-effectively through precision fermentation.
Partner with us on your next product.
![collaboverhead](https://dmcbio.com/wp-content/uploads/2023/08/collaboverhead.png)
TRUSTED PARTNERS
![Group 167](https://dmcbio.com/wp-content/uploads/2021/12/Group-167.png)
RECENT NEWS
![Subsequent Close of Series B Financing, Total Raised $39 million](https://dmcbio.com/wp-content/uploads/2022/01/DMC_Biotechnologies_1-1080x675.jpeg)
Subsequent Close of Series B Financing, Total Raised $39 million
31 January 2022 – DMC Biotechnologies, Inc. announces that strategic investors Continental Grain Company, through their venture arm Conti Ventures, and Toyobo have joined the Series B fundraising round, bringing the total raised to $39 million. DMC previously...
![DMC Appoints Ashley Jenkins as CFO](https://dmcbio.com/wp-content/uploads/2022/01/Ashley-Jenkins-800x675.jpg)
DMC Appoints Ashley Jenkins as CFO
5 January 2022 – DMC Biotechnologies has appointed Ashley Jenkins as Chief Financial Officer (CFO). Ashley joins DMC from Felix Energy where she has worked since 2013. Ashley joins DMC’s Boulder, Colorado office. Ashley Jenkins…
![DMC Announces First Close of Series B Financing, Raising $34 million](https://dmcbio.com/wp-content/uploads/2021/12/Series-B.jpg)
DMC Announces First Close of Series B Financing, Raising $34 million
2 December 2021 – DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy…
![DMC’s Downstream Processing Proven At Scale](https://dmcbio.com/wp-content/uploads/2021/12/EW-Biotech-Facility-2021.jpg)
DMC’s Downstream Processing Proven At Scale
13 May 2021 – DMC Biotechnologies has completed downstream processing for its first product, the amino acid L-alanine. The downstream processing was done at EW Biotech in Leuna, Germany following the successful demonstration of…
![1-1-1440w](https://dmcbio.com/wp-content/uploads/2022/03/1-1-1440w.jpg)